<p>Peachtree Investment Partners LLC 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在禮來公司的持倉減少了 7.2%。該基金在季度內出售了 1,984 股後，持有該公司 25,627 股股票。禮來公司約佔 Peachtree Investment Partners LLC 持有資產的 7.4%，是其第三大持倉。Peachtree Investment Partners LLC 在禮來公司的持倉在最近的報告期末價值為 19,784,000 美元。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<ul>
<li>目前哪個醫療保健股票是最佳購買？</li>
</ul>
<p>其他對沖基金和機構投資者最近也對該公司的持倉進行了調整。Swisher Financial Concepts Inc. 在第四季度將其在禮來公司的股份增加了 7.7%。Swisher Financial Concepts Inc. 現在擁有 1,187 股該公司的股票，價值 916,000 美元，在此期間又購買了 85 股。加拿大豐業銀行在第四季度將其在禮來公司的股份增加了 94.3%。加拿大豐業銀行現在擁有 366,407 股該公司的股票，價值 282,885,000 美元，在此期間又購買了 177,831 股。Shelton Capital Management 在第四季度將其在禮來公司的股份增加了 6.1%。Shelton Capital Management 現在擁有 17,821 股該公司的股票，價值 13,758,000 美元，在此期間又購買了 1,032 股。Rollins Financial Advisors LLC 在第四季度將其在禮來公司的股份增加了 1.1%。Rollins Financial Advisors LLC 現在擁有 1,732 股該公司的股票，價值 1,337,000 美元，在上個季度又獲得了 19 股。最後，Rathbones Group PLC 在第四季度將其在禮來公司的股份增加了 20.9%。Rathbones Group PLC 現在擁有 189,746 股該公司的股票，價值 146,484,000 美元，在此期間又獲得了 32,850 股。82.53% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師升級和降級</h2>
<p>LLY 曾受到多份分析師報告的關注。摩根士丹利在 3 月 6 日的報告中對禮來公司的股票設定了 1,146.00 美元的目標價。Leerink Partners 在 1 月 17 日的報告中對禮來公司的股票設定了 950.00 美元的目標價。花旗集團在 1 月 28 日的報告中將禮來公司的股票目標價從 1,250.00 美元下調至 1,190.00 美元，並給予該公司 “買入” 評級。StockNews.com 在 2 月 7 日的研究報告中將禮來公司的股票評級從 “持有” 上調至 “買入”。最後，Berenberg Bank 在 1 月 16 日的研究報告中對禮來公司的股票設定了 970.00 美元的目標價。三位研究分析師對該股票給予了 “持有” 評級，十七位分析師給予了 “買入” 評級。根據 MarketBeat 的數據，禮來公司目前的平均評級為 “適度買入”，共識目標價為 1,009.72 美元。</p>
<ul>
<li>價格目標顯示這三隻股票接近 1 萬億美元的標誌</li>
</ul>
<p><strong>獲取我們最新的 LLY 股票分析</strong></p>
<h2>內部買入和賣出</h2>
<p>在其他禮來公司的新聞中，首席會計官 Donald A. Zakrowski 於 3 月 13 日星期四出售了 1,000 股該公司的股票。該股票以平均價格 818.24 美元出售，總價值為 818,240.00 美元。出售後，首席會計官現在擁有 5,840 股該公司的股票，價值約 4,778,521.60 美元。這筆交易代表了其持倉的 14.62% 的減少。該出售在向 SEC 提交的文件中披露，可以通過 SEC 網站訪問。當前 0.13% 的股票由公司內部人士持有。</p>
<h2>禮來公司股票下跌 2.2%</h2>
<ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
<p>禮來公司的股票在週二以 722.03 美元開盤。該公司的流動比率為 1.15，速動比率為 0.97，債務與股本比率為 2.00。禮來公司的 12 個月低點為 677.09 美元，12 個月高點為 972.53 美元。該公司的 50 日移動平均線為 846.64 美元，200 日移動平均線為 830.05 美元。該股票的市值為 6846.1 億美元，市盈率為 61.66，市盈增長比率為 1.40，貝塔值為 0.51。</p>
<p>禮來公司（NYSE:LLY - 獲取免費報告）在 2 月 6 日星期四發佈了其季度財報。該公司報告季度每股收益為 5.32 美元，低於分析師一致預期的 5.45 美元，差額為 0.13 美元。禮來公司的股本回報率為 85.24%，淨利潤率為 23.51%。股票研究分析師預測，禮來公司在當前年度將發佈 23.48 美元的每股收益。</p>
<p>禮來公司宣佈其董事會已於 12 月 9 日星期一啓動了一項股票回購計劃，允許公司回購 150 億美元的流通股。該回購授權允許公司通過公開市場購買最多 2% 的股票。股票回購計劃通常表明公司的領導層認為其股票被低估。</p>
<h2>禮來公司公司簡介</h2>
<p>（免費報告）</p>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普、胰島素利普原料、胰島素利普混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>特色故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過禮來公司</li>
<li>股票情緒分析：它是如何運作的</li>
<li>CrowdStrike 的商譽策略能否帶來收入增長？</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>NIO 能否克服中美關税的逆風？</li>
<li>如何開始投資便士股票</li>
<li>道瓊斯的核賭注：在動盪時期的大膽舉措</li>
</ul>
<p><strong>想看看其他對禮來持有 LLY 的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取禮來公司（NYSE:LLY - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在你考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>Peachtree Investment Partners LLC 在第四季度減少了對禮來的持股，降幅為 7.2%，目前持有 25,627 股，價值約為 1978 萬美元。其他機構投資者也調整了他們的持倉，其中諾瓦斯科舍銀行和 Rathbones Group PLC 的增持尤為顯著。禮來的股票獲得了多位分析師的升級，市場共識目標價為 1,009.72 美元。該股票目前下跌 2.2%，交易價格為 722.03 美元，市值為 6846.1 億美元</p>

<p>Peachtree Investment Partners LLC cut its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,627 shares of the company's stock after selling 1,984 shares during the quarter. Eli Lilly and Company makes up about 7.4% of Peachtree Investment Partners LLC's holdings, making the stock its 3rd biggest position. Peachtree Investment Partners LLC's holdings in Eli Lilly and Company were worth $19,784,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Peachtree Investment Partners LLC 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在禮來公司的持倉減少了 7.2%。該基金在季度內出售了 1,984 股後，持有該公司 25,627 股股票。禮來公司約佔 Peachtree Investment Partners LLC 持有資產的 7.4%，是其第三大持倉。Peachtree Investment Partners LLC 在禮來公司的持倉在最近的報告期末價值為 19,784,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪個醫療保健股票是最佳購買？</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swisher Financial Concepts Inc. grew its position in shares of Eli Lilly and Company by 7.7% during the 4th quarter. Swisher Financial Concepts Inc. now owns 1,187 shares of the company's stock worth $916,000 after buying an additional 85 shares during the period. Bank of Nova Scotia lifted its stake in Eli Lilly and Company by 94.3% in the fourth quarter. Bank of Nova Scotia now owns 366,407 shares of the company's stock valued at $282,885,000 after buying an additional 177,831 shares during the period. Shelton Capital Management grew its position in shares of Eli Lilly and Company by 6.1% during the 4th quarter. Shelton Capital Management now owns 17,821 shares of the company's stock worth $13,758,000 after buying an additional 1,032 shares during the period. Rollins Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Rollins Financial Advisors LLC now owns 1,732 shares of the company's stock valued at $1,337,000 after acquiring an additional 19 shares during the last quarter. Finally, Rathbones Group PLC raised its position in shares of Eli Lilly and Company by 20.9% in the 4th quarter. Rathbones Group PLC now owns 189,746 shares of the company's stock valued at $146,484,000 after acquiring an additional 32,850 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也對該公司的持倉進行了調整。Swisher Financial Concepts Inc. 在第四季度將其在禮來公司的股份增加了 7.7%。Swisher Financial Concepts Inc. 現在擁有 1,187 股該公司的股票，價值 916,000 美元，在此期間又購買了 85 股。加拿大豐業銀行在第四季度將其在禮來公司的股份增加了 94.3%。加拿大豐業銀行現在擁有 366,407 股該公司的股票，價值 282,885,000 美元，在此期間又購買了 177,831 股。Shelton Capital Management 在第四季度將其在禮來公司的股份增加了 6.1%。Shelton Capital Management 現在擁有 17,821 股該公司的股票，價值 13,758,000 美元，在此期間又購買了 1,032 股。Rollins Financial Advisors LLC 在第四季度將其在禮來公司的股份增加了 1.1%。Rollins Financial Advisors LLC 現在擁有 1,732 股該公司的股票，價值 1,337,000 美元，在上個季度又獲得了 19 股。最後，Rathbones Group PLC 在第四季度將其在禮來公司的股份增加了 20.9%。Rathbones Group PLC 現在擁有 189,746 股該公司的股票，價值 146,484,000 美元，在此期間又獲得了 32,850 股。82.53% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>LLY has been the subject of a number of analyst reports. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, February 7th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $1,009.72.</p>
<div class="lb-trans"><p>LLY 曾受到多份分析師報告的關注。摩根士丹利在 3 月 6 日的報告中對禮來公司的股票設定了 1,146.00 美元的目標價。Leerink Partners 在 1 月 17 日的報告中對禮來公司的股票設定了 950.00 美元的目標價。花旗集團在 1 月 28 日的報告中將禮來公司的股票目標價從 1,250.00 美元下調至 1,190.00 美元，並給予該公司 “買入” 評級。StockNews.com 在 2 月 7 日的研究報告中將禮來公司的股票評級從 “持有” 上調至 “買入”。最後，Berenberg Bank 在 1 月 16 日的研究報告中對禮來公司的股票設定了 970.00 美元的目標價。三位研究分析師對該股票給予了 “持有” 評級，十七位分析師給予了 “買入” 評級。根據 MarketBeat 的數據，禮來公司目前的平均評級為 “適度買入”，共識目標價為 1,009.72 美元。</p>
</div><ul>
<li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li>
</ul>
<div class="lb-trans"><ul>
<li>價格目標顯示這三隻股票接近 1 萬億美元的標誌</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 LLY 股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買入和賣出</h2>
</div><p>In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他禮來公司的新聞中，首席會計官 Donald A. Zakrowski 於 3 月 13 日星期四出售了 1,000 股該公司的股票。該股票以平均價格 818.24 美元出售，總價值為 818,240.00 美元。出售後，首席會計官現在擁有 5,840 股該公司的股票，價值約 4,778,521.60 美元。這筆交易代表了其持倉的 14.62% 的減少。該出售在向 SEC 提交的文件中披露，可以通過 SEC 網站訪問。當前 0.13% 的股票由公司內部人士持有。</p>
</div><h2>Eli Lilly and Company Stock Down 2.2 %</h2>
<div class="lb-trans"><h2>禮來公司股票下跌 2.2%</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
</div><p>Shares of LLY opened at $722.03 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm's 50 day moving average is $846.64 and its 200-day moving average is $830.05. The stock has a market capitalization of $684.61 billion, a PE ratio of 61.66, a P/E/G ratio of 1.40 and a beta of 0.51.</p>
<div class="lb-trans"><p>禮來公司的股票在週二以 722.03 美元開盤。該公司的流動比率為 1.15，速動比率為 0.97，債務與股本比率為 2.00。禮來公司的 12 個月低點為 677.09 美元，12 個月高點為 972.53 美元。該公司的 50 日移動平均線為 846.64 美元，200 日移動平均線為 830.05 美元。該股票的市值為 6846.1 億美元，市盈率為 61.66，市盈增長比率為 1.40，貝塔值為 0.51。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>禮來公司（NYSE:LLY - 獲取免費報告）在 2 月 6 日星期四發佈了其季度財報。該公司報告季度每股收益為 5.32 美元，低於分析師一致預期的 5.45 美元，差額為 0.13 美元。禮來公司的股本回報率為 85.24%，淨利潤率為 23.51%。股票研究分析師預測，禮來公司在當前年度將發佈 23.48 美元的每股收益。</p>
</div><p>Eli Lilly and Company declared that its board has initiated a share buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.</p>
<div class="lb-trans"><p>禮來公司宣佈其董事會已於 12 月 9 日星期一啓動了一項股票回購計劃，允許公司回購 150 億美元的流通股。該回購授權允許公司通過公開市場購買最多 2% 的股票。股票回購計劃通常表明公司的領導層認為其股票被低估。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>禮來公司公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普、胰島素利普原料、胰島素利普混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Can NIO Overcome U.S.-China Tariff Headwinds?</li>
<li>How to start investing in penny stocks</li>
<li>Dow's Nuclear Gamble: A Bold Step in Turbulent Times</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過禮來公司</li>
<li>股票情緒分析：它是如何運作的</li>
<li>CrowdStrike 的商譽策略能否帶來收入增長？</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>NIO 能否克服中美關税的逆風？</li>
<li>如何開始投資便士股票</li>
<li>道瓊斯的核賭注：在動盪時期的大膽舉措</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對禮來持有 LLY 的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取禮來公司（NYSE:LLY - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Peachtree Investment Partners LLC 在禮來公司（NYSE:LLY）持有價值 1978 萬美元的股票頭寸